Pathology: es-BC - HER2 positive - (neo)adjuvant (NA); la/mBC - HER2 positive - 1st Line (L1);
| es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | ||
| GeparQuinto, 2012 | SYSUCC-002, 2022 | ||
| trastuzumab plus endocrine therapy | 1 | T1 | |
| trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | 1 | T1 | |
| trastuzumab plus chemotherapy | 0 | T0 | |
| lapatinib plus epirubicin and cyclophosphamide followed by docetaxel | 0 | T0 |